Mometasone furoate

Mometasone furoate (Sch32088) is a glucocorticoid receptor agonist with anti-inflammatory and anti-allergic activity. Mometasone furoate acts as a corticosteroid agent and used for topical applications in chronic skin eczema and airway inflammation management of asthma in vivo^[1] IC50 & Target: IC50: Glucocorticoid Receptor In Vitro: Mometasone furoate binds to a glucocorticoid receptor causes conformational changes in the receptor, separation from chaperones, and the receptor moves to the nucleus^[1].
Mometasone furoate (0.1-10 μM; 2h before LPS stimulation) strongly inhibits LPS-stimulated nitrite production in a concentration-dependent manner in J774 macrophages, The IC50 value is 0.00024 μM for Mometasone furoate in J774 cells^[1].
Mometasone furoate (0.1-10 μM; 2h before LPS stimulation) is more potent than DEX, it significantly inhibits iNOS expression at a 0.01 µM concentration whereas Dex became active at 0.1 µM. Additionally, the inhibition of cox-2 protein expression at 0.01 μM is 79% for Mometasone furoate and 39% for Dex^[1].